Loading cancer entity…
Loading cancer entity…
Clinical trials
8,122 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,291)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03767725 | Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma | unknown | Phase 1 | 10 | Shenzhen Second People's HospitalOTHER | 1 | Dec 10, 2018 | clinicaltrials |
| NCT03767751 | A Feasibility and Safety Study of Dual Specificity CD38 and BCMA CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma | unknown | Phase 1 / Phase 2 | 80 | Chinese PLA General HospitalOTHER | 1 | Dec 7, 2018 | clinicaltrials |
| NCT00923520 | A Phase 1, Dose Escalation Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous Dimethane Sulfonate (DMS612) in Advanced Malignancies | completed | Phase 1 | 60 | National Cancer Institute (NCI)NIH | 1 | Dec 5, 2018 | clinicaltrials |
| NCT03346642 | Two Stage Study of Combination of Chemotherapy, SHR-1210 and/or Decitabine for Relapsed/Refractory PMBCLs | unknown | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Dec 3, 2018 | clinicaltrials |
| NCT01401530 | E7777 for the Treatment of Patients With Peripheral T-Cell Lymphoma | completed | Phase 1 | 13 | Eisai Co., Ltd.INDUSTRY | 1 | Nov 23, 2018 | clinicaltrials |
| NCT02343666 | HIV-Resistant Gene Modified Stem Cells and Chemotherapy in Treating Patients With Lymphoma With HIV Infection | withdrawn | Phase 1 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Nov 20, 2018 | clinicaltrials |
| NCT01306643 | Safety and Efficacy Study of Idelalisib (GS-1101, CAL-101) in Patients With Previously Treated Low-grade Lymphoma | completed | Phase 1 / Phase 2 | 18 | Gilead SciencesINDUSTRY | 1 | Nov 19, 2018 | clinicaltrials |
| NCT01645930 | Phase 1 Pharmacokinetic Study of Oral Ixazomib Plus Lenalidomide and Dexamethasone in Adult Asian Participants With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 43 | Millennium Pharmaceuticals, Inc.INDUSTRY | 3 | Nov 8, 2018 | clinicaltrials |
| NCT00790842 | Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction(PrE1003) | terminated | Phase 1 / Phase 2 | 63 | PrECOG, LLC.OTHER | 1 | Oct 24, 2018 | clinicaltrials |
| NCT01342289 | Shorter Course Tacrolimus After Nonmyeloablative, Related Donor BMT With High-dose Posttransplantation Cyclophosphamide | completed | Phase 1 | 127 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Oct 17, 2018 | clinicaltrials |
| NCT03706547 | Anti-CD19/BCMA Bispecific CAR-T Cell Therapy for R/R MM | unknown | Phase 1 | 20 | Peng LiuOTHER | 1 | Oct 16, 2018 | clinicaltrials |
| NCT02075021 | Phase I/II Trial of the Combination of Lenalidomide (Revlimid) and Nab-paclitaxel (Abraxane) in the Treatment of Relapsed/Refractory Multiple Myeloma(rev/abraxane) | terminated | Phase 1 / Phase 2 | 3 | NYU Langone HealthOTHER | 1 | Oct 15, 2018 | clinicaltrials |
| NCT00231166 | Safety, Efficacy, Dose-finding Study of a Monoclonal Antibody in Patients With Multiple Myeloma | completed | Phase 1 | 33 | Novartis PharmaceuticalsINDUSTRY | 2 | Oct 11, 2018 | clinicaltrials |
| NCT00024466 | Chemotherapy, Vaccine Therapy, and Stem Cell Transplantation in Patients With Newly Diagnosed Multiple Myeloma | completed | Phase 1 / Phase 2 | 28 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01590732 | Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma | completed | Phase 1 | 22 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 19, 2018 | clinicaltrials |
| NCT01355705 | Phase 1-2 Amrubicin in Combo With Lenalidomide + Weekly Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 14 | Michaela LiedtkeOTHER | 1 | Sep 18, 2018 | clinicaltrials |
| NCT02602067 | 131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients(Tenatumomab) | terminated | Phase 1 | 2 | sigma-tau i.f.r. S.p.A.INDUSTRY | 2 | Sep 18, 2018 | clinicaltrials |
| NCT01672736 | A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma | terminated | Phase 1 / Phase 2 | 19 | University Health Network, TorontoOTHER | 2 | Sep 13, 2018 | clinicaltrials |
| NCT02462525 | Dose-Escalation Study of ABBV-838, an Antibody Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma | terminated | Phase 1 | 74 | AbbVieINDUSTRY | 4 | Sep 13, 2018 | clinicaltrials |
| NCT02728700 | Sirolimus and Mycophenolate Mofetil in Preventing GVHD in Patients With Hematologic Malignancies Undergoing HSCT | terminated | Phase 1 | 1 | Stanford UniversityOTHER | 1 | Sep 12, 2018 | clinicaltrials |
| NCT01950273 | Pharmacokinetics and Pharmacodynamics of BI 695500 vs. Rituximab as First Line-treatment in Patients With Low Tumor Burden Follicular Lymphoma | completed | Phase 1 | 95 | Boehringer IngelheimINDUSTRY | 13 | Sep 5, 2018 | clinicaltrials |
| NCT01272466 | Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma | completed | Phase 1 / Phase 2 | 40 | Herlev HospitalOTHER | 1 | Aug 31, 2018 | clinicaltrials |
| NCT02228512 | Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas | withdrawn | Phase 1 / Phase 2 | 0 | National Cancer Institute (NCI)NIH | 0 | Aug 31, 2018 | clinicaltrials |
| NCT01707264 | Phase 1/2, Open Label, Dose Escalation Study of NEOD001 in Subjects With Light Chain (AL) Amyloidosis | completed | Phase 1 / Phase 2 | 69 | Prothena Biosciences Ltd.INDUSTRY | 1 | Aug 28, 2018 | clinicaltrials |
| NCT00779584 | A Dose-escalation Study of MK-8776 (SCH 900776) With and Without Gemcitabine in Participants With Solid Tumors or Lymphoma (MK-8776-002/P05248) | completed | Phase 1 | 45 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2018 | clinicaltrials |
| NCT00901615 | Lenalidomide and R-CHOP in B-cell Lymphoma(R2CHOP-1) | completed | Phase 1 / Phase 2 | 108 | Lymphoma Study AssociationOTHER | 1 | Aug 23, 2018 | clinicaltrials |
| NCT02030483 | Palbociclib in Combination With Lenalidomide and Dexamethasone for Multiple Myeloma(PD + RD) | terminated | Phase 1 | 9 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 22, 2018 | clinicaltrials |
| NCT00777114 | Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy | completed | Phase 1 | 31 | Weill Medical College of Cornell UniversityOTHER | 1 | Aug 13, 2018 | clinicaltrials |
| NCT02702141 | A Safety Study of SGN-CD19B in Patients With B-cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Aug 13, 2018 | clinicaltrials |
| NCT00012298 | Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | terminated | Phase 1 / Phase 2 | 81 | National Cancer Institute (NCI)NIH | 1 | Aug 9, 2018 | clinicaltrials |
| NCT00701103 | Dose Escalation Trial of Dalotuzumab (MK-0646) in Advanced Solid Tumors and Multiple Myeloma (MK-0646-001) | completed | Phase 1 | 80 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 8, 2018 | clinicaltrials |
| NCT01428492 | Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma(PKB115125) | completed | Phase 1 | 90 | NovartisINDUSTRY | 5 | Aug 8, 2018 | clinicaltrials |
| NCT01690143 | Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation | completed | Phase 1 / Phase 2 | 45 | University of Alabama at BirminghamOTHER | 1 | Aug 7, 2018 | clinicaltrials |
| NCT03607643 | A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies | unknown | Phase 1 / Phase 2 | 160 | Leaf Vertical Inc.INDUSTRY | 1 | Jul 31, 2018 | clinicaltrials |
| NCT01777243 | A Study to Evaluate the Safety of GSK2398852 When Co-administered With GSK2315698 in Patients With Systemic Amyloidosis | completed | Phase 1 | 25 | GlaxoSmithKlineINDUSTRY | 1 | Jul 24, 2018 | clinicaltrials |
| NCT01484015 | Prolonged or Standard Infusion of Cefepime Hydrochloride in Treating Patients With Febrile Neutropenia | completed | Phase 1 | 70 | Wake Forest University Health SciencesOTHER | 1 | Jul 18, 2018 | clinicaltrials |
| NCT02071888 | Study of the Glutaminase Inhibitor CB-839 in Hematological Tumors | completed | Phase 1 | 25 | Calithera Biosciences, IncINDUSTRY | 1 | Jul 18, 2018 | clinicaltrials |
| NCT03528421 | Assessment of Safety and Efficacy of IM19 for Relapsed or Refractory NHL Patients | unknown | Phase 1 | 30 | Beijing Immunochina Medical Science & Technology Co., Ltd.INDUSTRY | 1 | Jul 16, 2018 | clinicaltrials |
| NCT01484626 | Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma(BVRD) | terminated | Phase 1 / Phase 2 | 3 | Loyola UniversityOTHER | 1 | Jul 10, 2018 | clinicaltrials |
| NCT00001830 | Donor Th2 Cells to Prevent Graft-Versus-Host Disease in Bone Marrow Transplants | completed | Phase 1 | 110 | National Cancer Institute (NCI)NIH | 1 | Jul 5, 2018 | clinicaltrials |
| NCT01910428 | L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) for Treatment of Adult Patients With ALL or LBL | terminated | Phase 1 | 14 | ERYtech PharmaINDUSTRY | 1 | Jul 5, 2018 | clinicaltrials |
| NCT02168907 | CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma | terminated | Phase 1 | 1 | Wake Forest University Health SciencesOTHER | 1 | Jul 2, 2018 | clinicaltrials |
| NCT01050764 | Haploidentical Allogeneic Transplant With Post-transplant Infusion of Regulatory T-cells | terminated | Phase 1 / Phase 2 | 10 | Everett MeyerOTHER | 1 | Jun 27, 2018 | clinicaltrials |
| NCT01563302 | Phase 1/2, Open-label, Dose-escalation Study of IONIS-STAT3Rx, Administered to Patients With Advanced Cancers | completed | Phase 1 / Phase 2 | 64 | Ionis Pharmaceuticals, Inc.INDUSTRY | 1 | Jun 25, 2018 | clinicaltrials |
| NCT00151320 | Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL | completed | Phase 1 / Phase 2 | 76 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 19, 2018 | clinicaltrials |
| NCT01979276 | Study of Pomalidomide, Dexamethasone, and Romidepsin for Rel/Ref Myeloma(Romi Poma) | terminated | Phase 1 / Phase 2 | 4 | Weill Medical College of Cornell UniversityOTHER | 1 | Jun 6, 2018 | clinicaltrials |
| NCT01129193 | AR-42 in Treating Patients With Advanced or Relapsed Multiple Myeloma, Chronic Lymphocytic Leukemia, or Lymphoma | completed | Phase 1 | 44 | Amir MortazaviOTHER | 1 | Jun 4, 2018 | clinicaltrials |
| NCT02203825 | Safety Study of Chimeric Antigen Receptor Modified T-cells Targeting NKG2D-Ligands | completed | Phase 1 | 12 | Celyad Oncology SAINDUSTRY | 1 | Jun 1, 2018 | clinicaltrials |
| NCT03540303 | Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma | unknown | Phase 1 | 15 | Henan Cancer HospitalOTHER_GOV | 1 | May 30, 2018 | clinicaltrials |
| NCT00504972 | Phase I Trial of Anti-CD74 (hLL1) Antibody Therapy in B Cell Malignancies | completed | Phase 1 | 23 | Weill Medical College of Cornell UniversityOTHER | 1 | May 29, 2018 | clinicaltrials |
Data updated 24 days agoSource updated Dec 10, 2018source: clinicaltrials